Dexamethasone

Generic Name: Dexamethasone

Brand Names: Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₉FO_₅

CAS Number: 50-02-2

Unique Ingredient Identifier: 7S5I7G3JQL

Background: Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.

Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.

Indication: Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.

Associated Conditions: Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes

Associated Therapies: -

Clinical Trials

FOLFOX Via HAI Plus Intravenous Irinotecan With or Without Bevacizumab Versus Systemic FOLFOXIRI With or Without Bevacizumab in Initially Unresectable RAS-mutated CRLM Patients

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Drug: Dexamethasone
Drug: Anisodamine
Drug: Oxaliplatin
Drug: Leucovorin
Drug: Fluorouracil
Drug: Irinotecan
Drug: Bevacizumab

First Posted Date: 2023-02-14

Last Posted Date: 2024-03-04

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 194

Registration Number: NCT05727163

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma

Phase 1

Recruiting

Conditions: Relapsed and/or Refractory Multiple Myeloma

Interventions: Drug: ICP-490
Drug: Dexamethasone

First Posted Date: 2023-02-09

Last Posted Date: 2024-04-09

Lead Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.

Target Recruit Count: 80

Registration Number: NCT05719701

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳
Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China

and more 3 locations

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Relapsed/Refractory Multiple Myeloma

Interventions: Drug: Isatuximab
Drug: Carfilzomib
Drug: Dexamethasone
Drug: Dexamethasone IV
Drug: Montelukast
Drug: Acetaminophen
Drug: Diphenhydramine
Drug: Methylprednisolone

First Posted Date: 2023-01-30

Last Posted Date: 2024-11-14

Lead Sponsor: Sanofi

Target Recruit Count: 74

Registration Number: NCT05704049

Locations: 🇦🇺
Investigational Site Number : 0360002, Wollongong, New South Wales, Australia
🇧🇷
Hospital Mae de Deus Site Number : 0760002, Porto Alegre, Rio Grande Do Sul, Brazil
🇦🇺
Investigational Site Number : 0360001, Fitzroy, Victoria, Australia

and more 14 locations

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Teclistamab (Tec)
Drug: Lenalidomide
Drug: Talquetamab
Drug: Dexamethasone
Drug: Bortezomib

First Posted Date: 2023-01-25

Last Posted Date: 2024-10-23

Lead Sponsor: University of Heidelberg Medical Center

Target Recruit Count: 130

Registration Number: NCT05695508

Locations: 🇩🇪
Charité University Medicin Berlin, Berlin, Germany
🇩🇪
Clinic Chemnitz gGmbH, Chemnitz, Germany
🇩🇪
University Clinic Technical University Dresden, Dresden, Germany

and more 8 locations

Dexamethasone vs Ondansetron After Cesarean Delivery

Phase 4

Completed

Conditions: Nausea and Vomiting, Postoperative
Cesarean Section Complications

Interventions: Drug: Dexamethasone
Drug: Ondansetron

First Posted Date: 2023-01-20

Last Posted Date: 2024-05-08

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 100

Registration Number: NCT05692245

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Elimination of Minimal Residual Disease After Transplant

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Dexamethasone
Drug: Isatuximab
Drug: Lenalidomide

First Posted Date: 2023-01-19

Last Posted Date: 2024-07-03

Lead Sponsor: Medical College of Wisconsin

Target Recruit Count: 31

Registration Number: NCT05690984

Locations: 🇺🇸
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin, United States

A Rollover Study of CC-122

Phase 1

Active, not recruiting

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: CC-122
Drug: Dexamethasone

First Posted Date: 2023-01-18

Last Posted Date: 2024-01-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT05688475

Locations: 🇳🇱
Local Institution - 400, Amsterdam, Netherlands
🇯🇵
Local Institution - 500, Koto-ku, Tokyo, Japan
🇺🇸
Local Institution - 100, New York, New York, United States

and more 4 locations

The Analgesic Efficacy of Two Bupivacaine Concentrations for Combined Ilioinguinal and Iliohypogastric Nerve Block in Postherniorrhaphy Pain

Early Phase 1

Not yet recruiting

Conditions: Hernia, Inguinal

Interventions: Drug: Dexamethasone
Drug: Bupivacaine

First Posted Date: 2023-01-18

Last Posted Date: 2023-01-18

Lead Sponsor: Tanta University

Target Recruit Count: 90

Registration Number: NCT05687981

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Phase 2

Recruiting

Conditions: Plasma Cell Myeloma

Interventions: Drug: Isatuximab intravenous (IV)
Drug: Cemiplimab (SAR439684)
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Pomalidomide
Drug: Isatuximab subcutaneous (SC)
Drug: Carfilzomib

First Posted Date: 2023-01-03

Last Posted Date: 2024-12-06

Lead Sponsor: Sanofi

Target Recruit Count: 70

Registration Number: NCT05669989

Locations: 🇳🇿
Investigational Site Number : 5540002, Auckland, New Zealand
🇺🇸
Washington University- Site Number : 8400001, Saint Louis, Missouri, United States
🇦🇺
Investigational Site Number : 0360006, Blacktown, New South Wales, Australia

and more 32 locations

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Phase 3

Recruiting

Conditions: Ocular Inflammation
Ocular Prostheses

Interventions: Other: Povidone
Drug: Dexamethasone
Drug: Hydrocortisone

First Posted Date: 2022-12-29

Last Posted Date: 2024-04-17

Lead Sponsor: Agnes

Target Recruit Count: 30

Registration Number: NCT05668455

Locations: 🇫🇷
Centre Hospitalier Universitaire de Rennes _ Pontchaillou, Rennes, France

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy